Nuvectis Pharma (NVCT) Insider Trading & Ownership $6.43 -0.39 (-5.72%) As of 03:47 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Nuvectis Pharma (NASDAQ:NVCT) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage30.52%Number OfInsiders Buying(Last 12 Months)3Amount OfInsider Buying(Last 12 Months)$2.02MNumber OfInsiders Selling(Last 12 Months)0 Get NVCT Insider Trade Alerts Want to know when executives and insiders are buying or selling Nuvectis Pharma stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address NVCT Insider Buying and Selling by Quarter Nuvectis Pharma Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame Start Date End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails6/20/2025Marlio Charles MosseriMajor ShareholderBuy5,603$7.99$44,767.97 6/18/2025Marlio Charles MosseriMajor ShareholderBuy28,043$8.05$225,746.15 6/17/2025Marlio Charles MosseriMajor ShareholderBuy5,399$8.11$43,785.89 5/12/2025Marlio Charles MosseriMajor ShareholderBuy21,167$8.11$171,664.37 5/8/2025Marlio Charles MosseriMajor ShareholderBuy2,650$8.65$22,922.50 5/6/2025Marlio Charles MosseriMajor ShareholderBuy12,444$8.59$106,893.96 2/7/2025Marlio Charles MosseriMajor ShareholderBuy240,000$5.00$1,200,000.00 12/24/2024Ron BentsurCEOBuy4,500$4.65$20,925.00 12/13/2024Marlio Charles MosseriMajor ShareholderBuy17,000$4.70$79,900.00 11/19/2024Enrique PoradosuInsiderBuy2,000$4.99$9,980.00 Get Insider Trades Delivered To Your InboxEnter your email address below to receive a concise daily summary of insider buying activity, insider selling activity and changes in hedge fund holdings. 11/15/2024Ron BentsurCEOBuy20,000$4.92$98,400.00 (Data available from 1/1/2013 forward) NVCT Insider Trading Activity - Frequently Asked Questions Who is on Nuvectis Pharma's Insider Roster? The list of insiders at Nuvectis Pharma includes Enrique Poradosu, Marlio Charles Mosseri, Ron Bentsur, and Shay Shemesh. Learn more on insiders at NVCT. What percentage of Nuvectis Pharma stock is owned by insiders? 30.52% of Nuvectis Pharma stock is owned by insiders. Learn more on NVCT's insider holdings. Which Nuvectis Pharma insiders have been buying company stock? The following insiders have purchased NVCT shares in the last 24 months: Enrique Poradosu ($13,125.00), Marlio Charles Mosseri ($1,895,680.84), and Ron Bentsur ($232,054.70). How much insider buying is happening at Nuvectis Pharma? Insiders have purchased a total of 371,381 NVCT shares in the last 24 months for a total of $2,140,860.54 bought. Nuvectis Pharma Key ExecutivesMr. Ron Bentsur M.B.A. (Age 58)Co-Founder, Chairman, CEO & President Compensation: $1.12MDr. Enrique Poradosu Ph.D. (Age 57)Co-Founder, Executive VP, Chief Scientific & Business Officer Compensation: $705.5kMr. Shay Shemesh (Age 40)Co-Founder, Executive VP, Chief Development & Operations Officer Compensation: $705.5kMr. Michael Carson CPA (Age 48)Vice President of Finance More Insider Trading Tools from MarketBeat Related Companies XNCR Insider Selling MRVI Insider Selling TSHA Insider Selling TRML Insider Selling BCYC Insider Selling TYRA Insider Selling TBPH Insider Selling SEPN Insider Selling SAGE Insider Selling PRME Insider Selling Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles 5 Stocks Insiders Are Selling That Analysts Say BuyStrategy Insiders Buy In While Analysts Predict Big UpsideThe Bottom Is in For These 3 Small-Cap Stocks Insiders Are Buying3 Catalysts Driving Plug Power’s Turnaround CaseInsider Selling Hits Market Leaders—Should You Be Worried? This page (NASDAQ:NVCT) was last updated on 8/13/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nuvectis Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nuvectis Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access